Cell-Targeted Delivery Evaluation Service

We evaluate lipid nanoparticles (including peptide-functionalized LNPs), extracellular vesicles (natural and engineered), polymer nanoparticles, antibody-drug conjugates, and biomimetic nanocarriers. The specific assay panel is customized to your vehicle type and cargo.

We include receptor blocking experiments (pre-incubation with free ligand or blocking antibody), competition with excess targeting moiety, and parallel evaluation on non-target cell lines. A specificity index is calculated to quantify selective uptake.

Yes. We design assays to measure functional activity of the delivered cargo, such as reporter gene expression (GFP, luciferase), target gene knockdown by qPCR/Western blot, or drug-induced phenotypic changes. The readout is selected based on your cargo and goals.

In vivo studies can be included as an optional extension, typically following a successful in vitro validation. We can assess tissue-specific accumulation, biodistribution, and therapeutic efficacy in relevant animal models. Scope and endpoints are defined per project.

We offer modular scoping. You can choose a limited panel (e.g., binding + uptake on one target cell line) or a full evaluation including functional activity and off-target profiling. Each project is quoted individually based on the agreed scope.

Each vehicle batch is characterized for particle size (dynamic light scattering), polydispersity index, zeta potential, and targeting moiety density (by flow or HPLC) before cellular testing. All assays include internal controls and replicates.